Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Ji Hyun | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Lee, Je-Jung | - |
dc.contributor.author | Lee, Ho Sup | - |
dc.contributor.author | Eom, Hyeon-Seok | - |
dc.contributor.author | Do, Young Rok | - |
dc.contributor.author | Kim, Jin Seok | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.contributor.author | Shin, Dong-Yeop | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Kim, Ki-Hyun | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Jo, Jae-Cheol | - |
dc.contributor.author | Lee, Yoo Jin | - |
dc.contributor.author | Lee, Ji Yun | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Shim, Hyeok | - |
dc.contributor.author | Chang, Myung Hee | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Min, Chang-Ki | - |
dc.date.accessioned | 2022-02-25T19:40:54Z | - |
dc.date.available | 2022-02-25T19:40:54Z | - |
dc.date.created | 2022-02-09 | - |
dc.date.issued | 2021-08 | - |
dc.identifier.issn | 0939-5555 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/136895 | - |
dc.description.abstract | Carfilzomib, lenalidomide, and dexamethasone (KRd) effectively improve survival in patients with relapsed and refractory multiple myeloma (RRMM). However, the outcome of KRd treatment in Asian patients reflecting a general RRMM population outside of a clinical trial has not been reported. Fifty-five RRMM patients who were treated with carfilzomib in combination with Rd from the time of the first approval of KRd in the Republic of Korea were analyzed. The median age was 61 years. The percentage of patients with an ECOG performance status >= 3, creatinine clearance < 50 mL/min, high-risk cytogenetics, and >= 4 lines of prior treatment were 9%, 22%, 31%, and 27%, respectively. Forty-one patients started treatment with KRd, whereas the remaining 14 patients (25%) were added carfilzomib during the Rd treatment. In the whole cohort, the overall response rate was 73% and progression-free survival was 8.8 months. The addition of carfilzomib in patients who were refractory or had disease progression during Rd treatment reattained a response in half of the patients. The advantage of carfilzomib with Rd was significant in patients in the first relapse. Toxicity profile was acceptable, excluding severe infections. Carfilzomib in combination with Rd is effective and has a reasonable adverse event rate in Asian patients with RRMM. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.title | Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.contributor.affiliatedAuthor | Kang, Ka-Won | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.identifier.doi | 10.1007/s00277-021-04407-0 | - |
dc.identifier.scopusid | 2-s2.0-85099360428 | - |
dc.identifier.wosid | 000607773800001 | - |
dc.identifier.bibliographicCitation | ANNALS OF HEMATOLOGY, v.100, no.8, pp.2051 - 2059 | - |
dc.relation.isPartOf | ANNALS OF HEMATOLOGY | - |
dc.citation.title | ANNALS OF HEMATOLOGY | - |
dc.citation.volume | 100 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 2051 | - |
dc.citation.endPage | 2059 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordAuthor | Asia | - |
dc.subject.keywordAuthor | Carfilzomib | - |
dc.subject.keywordAuthor | Lenalidomide | - |
dc.subject.keywordAuthor | Real-world | - |
dc.subject.keywordAuthor | Relapsed and refractory multiple myeloma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.